Sequencing TKIs for progressive disease

Sam reviews second-line sunitinib, third-line regorafenib, and fourth-line ripretinib with trial outcomes.

Play episode from 07:35

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!